These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36998143)

  • 21. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
    Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
    Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
    Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Avelumab for the treatment of urothelial cancer.
    Rodriguez-Vida A; Bellmunt J
    Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.
    Zhang L; Geng Z; Hao B; Geng Q
    Cancer Control; 2022; 29():10732748221111296. PubMed ID: 35926155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
    Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
    Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
    Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS
    Cancer; 2018 Jan; 124(2):271-277. PubMed ID: 28960263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.
    Johnson ML; Strauss J; Patel MR; Garon EB; Eaton KD; Neskorik T; Morin J; Chao R; Halmos B
    Clin Lung Cancer; 2023 May; 24(3):218-227. PubMed ID: 36890020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Durvalumab for the treatment of non-small cell lung cancer.
    Murakami S
    Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
    Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
    Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
    Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
    Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durvalumab in non-small-cell lung cancer patients: current developments.
    Mezquita L; Planchard D
    Future Oncol; 2018 Feb; 14(3):205-222. PubMed ID: 29140105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
    Davick JJ; Frierson HF; Smolkin M; Gru AA
    Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.
    Mishra A; Kumar D; Gupta K; Lofland G; Sharma AK; Banka DS; Hobbs RF; Dannals RF; Rowe SP; Gabrielson E; Nimmagadda S
    Clin Cancer Res; 2023 Feb; 29(3):581-591. PubMed ID: 36449662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
    Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY
    Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
    Hong D; Rasco D; Veeder M; Luke JJ; Chandler J; Balmanoukian A; George TJ; Munster P; Berlin JD; Gutierrez M; Mita A; Wakelee H; Samakoglu S; Guan S; Dimery I; Graef T; Borazanci E
    Oncology; 2019; 97(2):102-111. PubMed ID: 31230047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
    Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
    Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.
    Baxi V; Lee G; Duan C; Pandya D; Cohen DN; Edwards R; Chang H; Li J; Elliott H; Pokkalla H; Glass B; Agrawal N; Lahiri A; Wang D; Khosla A; Wapinski I; Beck A; Montalto M
    Mod Pathol; 2022 Nov; 35(11):1529-1539. PubMed ID: 35840720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.